Cardiomyopathies

1. Front Matter

   Pages I-XIV

   PDF

2. Introduction

   1. Front Matter

      Pages 1-1

      PDF

   2. Definition, Classification and Terminology

      • E. G. J. Olsen, J. F. Goodwin

      Pages 3-5

3. Dilated Cardiomyopathy

   1. Front Matter

      Pages 7-7

      PDF

   2. Clinical Aspects

      • J. F. Goodwin

      Pages 9-18

   3. Pathology

      • E. G. J. Olsen, S. E. Trotter

      Pages 19-26

   4. Clinical Investigation: New Approaches

      • P. J. Richardson, H. J. F. Why

      Pages 27-45

   5. Prognosis and Management

      • E. M. Gilbert, A. Di Lenarda, J. B. O’Connell

      Pages 46-63

4. Hypertrophic Cardiomyopathy

   1. Front Matter

      Pages 65-65

      PDF

   2. Clinical Aspects

      • J. F. Goodwin

      Pages 67-84

   3. Pathology

      • E. G. J. Olsen, S. E. Trotter

      Pages 85-93

   4. Clinical Investigation: Current Approaches

      • P. J. Richardson, H. J. F. Why

      Pages 94-107

   5. Haemodynamic Disorders: Management and Prognosis

      • J. T. Stewart, W. J. McKenna

      Pages 108-143

5. Restrictive Cardiomyopathy

   1. Front Matter

      Pages 145-145

      PDF

   2. Clinical Aspects

      • J. F. Goodwin

      Pages 147-164

   3. Pathology

      • E. G. J. Olsen, S. E. Trotter

      Pages 165-172

   4. Doppler Echocardiographic Investigations

      • H. Acquatella

      Pages 173-189

6. Amyloid Heart Disease and Others

   1. Front Matter

      Pages 191-191

      PDF

   2. Amyloid Heart Disease and Cardiomyopathies Difficult To Classify

      • C. M. Oakley

      Pages 193-211

7. Experimental, Clinical, Immunological and Molecular Biological Research

   1. Front Matter

      Pages 213-213

      PDF

This book reviews the basic knowledge about the cardiomyopathies and re-enforces the well-known definitions and classification of cardiomyopathies and specific heart muscle diseases, respectively. It emphasizes the importance of maintaining the classification into hypertrophic, dilated and restrictive cardiomyopathies, even though there are exceptions. The term "realisations" in the title is used in the sense of "achievements" and alludes to the progress in the understanding of heart muscle diseases over the last three decades and also to the areas of knowledge still not fully explored, for example, the as yet un­ classified putative cardiomyopathies such as arrhythmogenic right ventricular dysplasia, long QT syndrome and syndrome X. The accurate and sensitive identification of major risk factors for sudden death in hypertrophic cardiomyopathy needs further study, as do the implications of a familial basis in some patients with dilated cardio­ myopathy. The "expectations" mentioned in the title centre around the molecular biological aspects of viral myocarditis and dilated cardio­ myopathy and their relationship to each other; around the auto­ immune basis for dilated cardiomyopathy and its implications for drug therapy and cardiac transplantation; and around molecular genetic techniques for identifying the genes involved in hypertrophic cardiomyopathy that will be developed further. These will have implications for pre-natal recognition and for diagnosis in early life in apparently fit and active persons, and offer better prospects of prevention and cure.

• ADP-ATP-carrier
• autoantibodies
• cardiomyopathy
• clinical research
• diagnosis
• gene
• genetics
• heart
• heart disease
• heart muscle disease
• prenatal diagnosis
• research
• transplantation
• treatment
• viral heart disease

• Department of Cardiology, Royal Postgraduate Medical School, London, UK

  J. F. Goodwin

• Department of Histopathology, Royal Brompton National Heart and Lung Hospital London, London, UK

  E. G. J. Olsen

Policies and ethics